DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.39
-0.36 (-5.33%)
Aug 28, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,072,600
Market Cap
344.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Lyell Immunopharma | 161 |
| Sutro Biopharma | 128 |
| Foghorn Therapeutics | 106 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Agenus | 81 |
| Upstream Bio | 75 |
DMAC News
- 19 days ago - DiaMedica Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings
- 19 days ago - DiaMedica Therapeutics Earnings release: Q2 2026 - Filings
- 20 days ago - DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c) - TheFly
- 20 days ago - DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 26 days ago - DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
- 6 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly